Reducing the risk of transfusion-transmitted cytomegalovirus infection: A systematic review and meta-analysis

Maria Mainou, Fares Alahdab, Aaron A.R. Tobian, Noor Asi, Khaled Mohammed, M. Hassan Murad, Brenda J. Grossman

Research output: Contribution to journalArticle

Abstract

BACKGROUND Leukoreduced (LR) or cytomegalovirus (CMV)-seronegative cellular blood components are commonly used to reduce the risk of transfusion-transmitted CMV infection in high-risk patients. STUDY DESIGN AND METHODS We performed a systematic review and meta-analysis to evaluate the evidence for the use of LR cellular blood components with or without concurrent CMV testing of donor units in patients undergoing chemotherapy or solid organ and hematopoietic stem cell transplantation, in pregnant women, in very-low-birthweight infants, and in patients with primary immunodeficiency. We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus from 1980 through February 2015. Studies were included if they had a comparison group. Two independent reviewers selected and appraised studies. Meta-analysis was performed when appropriate. RESULTS Of 457 studies screened, 11 were eligible. One study was excluded from the meta-analysis because the comparison performed differed significantly from the others. Meta-analysis of five studies that compared leukoreduction to transfusing CMV-untested blood components showed no significant difference in clinical CMV infection (relative risk [RR], 0.26; 95% confidence interval [CI], 0.04-1.57) or laboratory CMV infection (RR, 0.33; 95% CI, 0.08-1.37). Meta-analysis of three studies that compared leukoreduction to transfusing CMV-seronegative cellular components showed no significant difference in laboratory CMV infection (RR, 2.18; 95% CI, 0.96-4.98). Meta-analysis of two studies that compared adding CMV testing to leukoreduction (vs. leukoreduction alone) showed no significant difference in clinical or laboratory CMV infection. The certainty in estimates was low for all comparisons. CONCLUSION At present, the scientific evidence does not favor a single strategy for reducing the risk of transfusion-related CMV infection in high-risk patients.

Original languageEnglish (US)
Pages (from-to)1569-1580
Number of pages12
JournalTransfusion
Volume56
Issue number6
DOIs
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology

Fingerprint Dive into the research topics of 'Reducing the risk of transfusion-transmitted cytomegalovirus infection: A systematic review and meta-analysis'. Together they form a unique fingerprint.

  • Cite this